Mifepristone

Mifepristone 구조식 이미지
카스 번호:
84371-65-3
상품명:
Mifepristone
동의어(영문):
RU486;Mifeprestone;Mifepristone INN;C-1073;r38486;ru486-6;VGX 410;MIFEGYNE;RU-38486;Mifeprex
CBNumber:
CB6351940
분자식:
C29H35NO2
포뮬러 무게:
429.6
MOL 파일:
84371-65-3.mol
MSDS 파일:
SDS

Mifepristone 속성

녹는점
195-198°C
알파
D20 +138.5° (c = 0.5 in chloroform)
끓는 점
544.13°C (rough estimate)
밀도
1.0731 (rough estimate)
굴절률
1.6290 (estimate)
저장 조건
2-8°C
용해도
DMSO(최대 40mg/ml) 또는 에탄올(최대 20mg/ml)에 용해됩니다.
물리적 상태
노란색 고체
산도 계수 (pKa)
12.94±0.60(Predicted)
색상
노란색
수용성
474.8ug/L(22.5ºC)
Merck
14,6186
안정성
제공된 대로 구매일로부터 1년 동안 안정적입니다. DMSO 또는 에탄올 용액은 -20°C에서 최대 3개월 동안 보관할 수 있습니다.
InChIKey
VKHAHZOOUSRJNA-GCNJZUOMSA-N
CAS 데이터베이스
84371-65-3(CAS DataBase Reference)
안전
  • 위험 및 안전 성명
  • 위험 및 사전주의 사항 (GHS)
위험품 표기 T
위험 카페고리 넘버 60-61
안전지침서 53-22-36/37/39-45
WGK 독일 3
RTECS 번호 KG2955000
HS 번호 29372900
유해 물질 데이터 84371-65-3(Hazardous Substances Data)
그림문자(GHS): GHS hazard pictograms
신호 어: Danger
유해·위험 문구:
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드
H360 태아 또는 생식능력에 손상을 일으킬 수 있음 생식독성 물질 구분 1A, 1B 위험 GHS hazard pictograms
예방조치문구:
P201 사용 전 취급 설명서를 확보하시오.
P308+P313 노출 또는 접촉이 우려되면 의학적인 조치· 조언를 구하시오.

Mifepristone MSDS


11b-[p-(Dimethylamino)phenyl]-17b-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one

Mifepristone C화학적 특성, 용도, 생산

개요

Mifepristone is an orally-active progesterone and glucocorticoid receptor antagonist indicated for use as a post-coital contraceptive. In addition to being an abortifacient, mifepristone is reported to be effective in the treatment of ocular hypertension; its potential therapeutic effect in hormone-dependent tumors is currently under investigation.

화학적 성질

Pale Yellow Solid

용도

Mifepristone is a progesterone receptor antagonist with partial agonist activity. Abortifacient.

Indications

Mifepristone is a progesterone receptor antagonist that has a high affinity for glucocorticoid receptors and little agonist effect.This drug has recently been approved for use in the United States for the treatment of hypercortisolism. At high doses, mifepristone blocks negative feedback of the hypothalamic–pituitary axis, thereby increasing endogenous corticotrophin and cortisol levels. Because mifepristone exerts its effects at the receptor level and not by altering glucocorticoid production, elevated serum cortisol and corticotrophin levels may not accurately reflect the effectiveness of the therapeutic regimen. Mifepristone does not inhibit cortisol binding to the mineralocorticoid receptor, so that the resulting corticotrophin disinhibition may cause potassium depletion. Thus, administration of a mineralocorticoid receptor antagonist such as spironolactone may be indicated with mifepristone. Hypoadrenalism, nausea, and drowsiness have been reported during prolonged administration of mifepristone.

World Health Organization (WHO)

Mifepristone, an antiprogesterone used in combination with a prostaglandin for the termination of early pregnancy, was introduced in 1990. Use of the combination has been associated with episodes of coronary spasm that are attributed to administration of the prostaglandin and which have resulted in several cases of cardiac infarction and ventricular fibrillation. At least one of these incidents has been fatal.

생물학적 활성

Selective antagonist at progesterone (PR) and glucocorticoid (GR) receptors in vitro and in vivo . Is a silent antagonist at PR and has a higher affinity than progesterone. Has higher affinity for GR than dexamethasone.

Pharmacokinetics

Following oral administration, mifepristone is rapidly absorbed, with a peak plasmaconcentration in approximately 90 minutes , an oral bioavailability of approximately 70%, and a term inal elimination half-life of 18 hours. It is 98% protein bound, primarily to album in and α1-acid glycoprotein. Mifepristone is metabolized primarily via CYP3A4 pathways involving mono- and di-N-demethylation and terminal hydroxylation of the 17-propynyl chain. The fact that approximately 83% of the drug is recovered in the feces and 9% in the urine suggests a biliary route of elimination. Mifepristone also demonstrates antiglucocorticoid activity.

Clinical Use

An antiprogestin is a substance that competes with progesterone for its receptor and, ultimately, prevents progesterone from binding to and activating its receptor. Because progesterone is integral to the continuation of an early pregnancy, it is expected that antipro-gestins will interfere with pregnancy maintenance. In 1982, the first antiproges tin, mifepristone (RU 486), was reported. Mifepristone was shown to interrupt early stages of implantation and pregnancy in humans.

참고 문헌

https://pubchem.ncbi.nlm.nih.gov/compound/mifepristone#section=Top
https://www.drugbank.ca/drugs/DB00834
https://www.drugs.com/cdi/mifepristone-tablets.html

Mifepristone 준비 용품 및 원자재

원자재

준비 용품


Mifepristone 공급 업체

글로벌( 538)공급 업체
공급자 전화 이메일 국가 제품 수 이점
Hebei Bonster Technology Co.,Limited
+8613315996897
bsterltd.wendy@gmail.com China 796 58
Hebei Kangcang new material Technology Co., LTD
+8619133911216
Jany1001@kangcang.com.cn China 338 58
Hong Kong Excellence Biotechnology Co., Ltd.
+86-86-18838029171 +8618126314766
ada@sh-teruiop.com China 892 58
Henan Tengmao Chemical Technology Co. LTD
+8615238638457
salesvip2@hntmhg.com China 415 58
Wuhan Haorong Biotechnology Co.,ltd
+8618565342920
sales@chembj.net China 269 58
Nantong Guangyuan Chemicl Co,Ltd
+undefined17712220823
admin@guyunchem.com China 616 58
Henan Senhaibao Pharmaceutical Technology Co., Ltd
+86-85246382586 +86-15118143473
anlenone888@gmail.com China 9 58
Shaanxi Franta Biotechnology Co., Ltd
+86-13082019107 +86-13082019107
admin@flanderff.com China 229 58
Sigma Audley
+86-18336680971 +86-18126314766
nova@sh-teruiop.com China 524 58
Shanghai Aosiris new Material Technology Co., LTD
+8615139564871
wrjmoon2000@163.com China 354 58

Mifepristone 관련 검색:

Copyright 2019 © ChemicalBook. All rights reserved